Overview

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

Status:
Completed
Trial end date:
2020-09-24
Target enrollment:
Participant gender:
Summary
The purpose of this multi-center study is to evaluate the efficacy and safety of daprodustat in subjects with anemia associated with CKD.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Darbepoetin alfa
Epoetin Alfa
Iron